Publications by authors named "Angela Abelo"

Claim this Profile
P
Population pharmacokinetic-pharmacodynamic modeling of co-administered N,N-dimethyltryptamine and harmine in healthy subjects.
Angela Äbelö, John W Smallridge, Robin von Rotz, Dario A Dornbierer, Klemens Egger

Biomed Pharmacother· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Examining the pharmacokinetic and pharmacodynamic interaction of N,N-dimethyltryptamine and harmine in healthy volunteers: Α factorial dose-escalation study.
Klemens Egger, Javier Jareño Redondo, Jovin Müller, Joëlle Dornbierer, John Smallridge

Biomed Pharmacother· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Enzyme Induction and Polymorphism on the Pharmacokinetics of Isoniazid and Rifampin in Tuberculosis/HIV Patients.
Jesper Sundell, Emile Bienvenu, Sofia Birgersson, Angela Äbelö, Michael Ashton

Antimicrob Agents Chemother· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Pharmacodynamic Modeling of Eflornithine-Based Treatments Against Late-Stage Gambiense Human African Trypanosomiasis and Efficacy Predictions of L-eflornithine-Based Therapy.
Carl Amilon, Mikael Boberg, Joel Tarning, Angela Äbelö, Michael Ashton

AAPS J· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of efavirenz-based ART on the pharmacokinetics of rifampicin and its primary metabolite in patients coinfected with TB and HIV.
Jesper Sundell, Emile Bienvenu, Angela Äbelö, Michael Ashton

J Antimicrob Chemother· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors Affecting the Pharmacokinetics of Pyrazinamide and Its Metabolites in Patients Coinfected with HIV and Implications for Individualized Dosing.
Jesper Sundell, Marie Wijk, Emile Bienvenu, Angela Äbelö, Kurt-Jürgen Hoffmann

Antimicrob Agents Chemother· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Model-Based Assessment of Variability in Isoniazid Pharmacokinetics and Metabolism in Patients Co-Infected With Tuberculosis and HIV: Implications for a Novel Dosing Strategy.
Jesper Sundell, Emile Bienvenu, David Janzén, Sofia Birgersson, Angela Äbelö

Clin Pharmacol Ther· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Pharmacokinetics and Pharmacogenetics of Ethambutol in Adult Patients Coinfected with Tuberculosis and HIV.
Jesper Sundell, Emile Bienvenu, Sofia Birgersson, Angela Äbelö, Michael Ashton

Antimicrob Agents Chemother· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concentration-QT Modeling Following Inhalation of the Novel Inhaled Phosphodiesterase-4 Inhibitor CHF6001 in Healthy Volunteers Shows an Absence of QT Prolongation.
Koen Jolling, Angela Äbelö, Nicolas Luyckx, Marie-Anna Nandeuil, Mirco Govoni

CPT Pharmacometrics Syst Pharmacol· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics of artesunate and dihydroartemisinin in pregnant and non-pregnant women with uncomplicated malaria in Burkina Faso: an open label trial.
Sofia Birgersson, Innocent Valea, Halidou Tinto, Maminata Traore-Coulibaly, Laeticia C Toe

Wellcome Open Res· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Simultaneous quantification of four first line antitubercular drugs and metabolites in human plasma by hydrophilic interaction chromatography and tandem mass spectrometry.
Jesper Sundell, Emile Bienvenu, Sofia Birgersson, Angela Äbelö, Michael Ashton

J Chromatogr B Analyt Technol Biomed Life Sci· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetic properties of artemisinin in healthy male Vietnamese volunteers.
Sofia Birgersson, Pham Van Toi, Nguyen Thanh Truong, Nguyen Thi Dung, Michael Ashton

Malar J· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics of a three-day chloroquine treatment in patients with Plasmodium vivax infection on the Thai-Myanmar border.
Richard Höglund, Younis Moussavi, Ronnatrai Ruengweerayut, Anurak Cheomung, Angela Äbelö

Malar J· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Artemether-lumefantrine co-administration with antiretrovirals: population pharmacokinetics and dosing implications.
Richard M Hoglund, Pauline Byakika-Kibwika, Mohammed Lamorde, Concepta Merry, Michael Ashton

Br J Clin Pharmacol· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics of artesunate and dihydroartemisinin during long-term oral administration of artesunate to patients with metastatic breast cancer.
Therese Ericsson, Antje Blank, Cornelia von Hagens, Michael Ashton, Angela Äbelö

Eur J Clin Pharmacol· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The evaluation of CYP2B6 inhibition by artemisinin antimalarials in recombinant enzymes and human liver microsomes.
Therese Ericsson, Collen Masimirembwa, Angela Abelo, Michael Ashton

Drug Metab Lett· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
External validation of the bilirubin-atazanavir nomogram for assessment of atazanavir plasma exposure in HIV-1-infected patients.
Dinko Rekić, Daniel Röshammar, Martin Bergstrand, Joel Tarning, Andrea Calcagno

AAPS J· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetic modeling and deconvolution of enantioselective absorption of eflornithine in the rat.
Carl-Christer Johansson, Peter Gennemark, Per Artursson, Angela Äbelö, Michael Ashton

J Pharmacokinet Pharmacodyn· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bilirubin-a potential marker of drug exposure in atazanavir-based antiretroviral therapy.
Dinko Rekić, Oskar Clewe, Daniel Röshammar, Leo Flamholc, Anders Sönnerborg

AAPS J· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Application of a combined effect compartment and binding model for gastric acid inhibition of AR-HO47108: a potassium competitive acid blocker, and its active metabolite AR-HO47116 in the dog.
Angela Abelö, Magdalena Andersson, Ann Aurell Holmberg, Mats O Karlsson

Eur J Pharm Sci· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gastric acid secretion in the dog: a mechanism-based pharmacodynamic model for histamine stimulation and irreversible inhibition by omeprazole.
Angela Abelö, Björn Holstein, Ulf G Eriksson, Johan Gabrielsson, Mats O Karlsson

J Pharmacokinet Pharmacodyn· August 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis